IGI Laboratories has entered a license, development, supply and marketing agreement with a large, global pharmaceutical company, to develop and manufacture a generic topical drug product developed at IGI, which will be licensed, marketed and distributed in the U.S. by its partner and/or its subsidiaries.   IGI has filed the ANDA associated with the product is eligible to receive milestones related to the filing and approval. IGI will also receive a share of the profits following approval and com...